Adding the drug trastuzumab to chemotherapy prevents cancer recurrence and improves survival in a majority of women with early stage HER2-positive breast cancer. But trastuzumab does not stop tumors from returning in about 25 percent of patients — and oncologists haven’t been able to identify these women before treatment. This situation may soon change, according to a Mayo Clinic study being presented this week at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.
EMBARGOED news release: Dr. Perez
Sound bites with Edith Perez, M.D., are available in the downloads below
Expert title for broadcast cg: Dr. Edith Perez, Mayo Clinic Oncologist